B-Cell Class Switching

How class switching works

Antibody molecules have two functional regions. The variable (V) tip is the antigen-binding hand — assembled from V, D, and J gene segments during B-cell development and refined by somatic hypermutation in germinal centers, it determines what the antibody recognizes. The constant (Fc) tail is what makes the antibody useful: it determines whether the antibody crosses the placenta, fixes complement, opsonizes bacteria for phagocytes, binds mast cells, or gets secreted into mucus. Class switching swaps the Fc without touching the V.

The mechanism centers on AID — activation-induced cytidine deaminase, an enzyme that converts cytosine bases to uracil in single-stranded DNA. AID's substrate is the chromosomal region between the V(D)J gene and a downstream constant gene. Each constant gene (Cμ, Cδ, Cγ3, Cγ1, Cα1, Cγ2, Cγ4, Cε, Cα2 in humans) is preceded by a switch region — a long, repetitive, GC-rich sequence containing AID's preferred WRC motif. Switch regions can be transcribed from intronic promoters; transcription forms R-loops (RNA-DNA hybrids with displaced single-stranded DNA) that expose ssDNA to AID attack.

When AID deaminates cytosines in two switch regions simultaneously — say Sμ and Sγ1 — the resulting uracils are recognized as DNA damage. Uracil-DNA glycosylase (UNG) excises them, leaving abasic sites. Apurinic/apyrimidinic endonuclease cleaves the backbone, generating single-strand breaks. When breaks occur on opposite strands close together, they convert into double-strand breaks. The mismatch repair machinery (MSH2/MSH6) can also process clustered uracils into double-strand breaks. Non-homologous end joining (NHEJ) then ligates the Sμ break to the Sγ1 break, splicing out the intervening DNA (which exits the cell as a circular byproduct) and bringing Cγ1 directly downstream of the V(D)J. The cell now makes IgG1 instead of IgM with the same antigen specificity.

This process consumes constant genes irreversibly. Once a B cell has switched past Cγ3 and Cγ1, those genes are gone — excised on a switch circle and degraded. Subsequent switching can only go to downstream genes. The chromosomal order (μ, δ, γ3, γ1, α1, γ2, γ4, ε, α2) imposes a directional constraint and biases sequential switching patterns observed in immune responses.

Worked example: switching from IgM to IgE in allergic disease

A patient develops allergic asthma. Inhaled house dust mite antigens (Der p 1, Der p 2) are taken up by dendritic cells in the airway and presented to CD4 T cells in mediastinal lymph nodes. The cytokine context — IL-25, IL-33, TSLP from epithelium plus IL-4 from initial T-cell activation — pushes naive CD4 cells into a Th2 program. These Th2 cells secrete more IL-4, IL-5, IL-13.

A naive B cell with a BCR specific for Der p 1 has been activated in the same lymph node and migrated into a germinal center. Here it encounters T follicular helper cells; CD40L on Tfh engages CD40 on the B cell, and IL-4 binds IL-4Rα. STAT6 phosphorylates, translocates to the nucleus, and induces germline transcription from the ε switch region — opening Sε to AID. Meanwhile, Sμ is always accessible because Cμ is the active gene being transcribed.

AID deaminates ~10 cytosines per switch region per division. After several rounds, enough double-strand breaks accumulate that NHEJ splices Sμ-Sε, deleting the intervening 100-150 kb of DNA containing Cδ, Cγ3, Cγ1, Cα1, Cγ2, and Cγ4. The B cell now expresses surface IgE specific for Der p 1. It differentiates into a plasma cell secreting IgE — which binds the high-affinity FcεRI receptor on tissue mast cells throughout the airway. The patient is now sensitized: the next exposure to house dust mite will cross-link IgE on mast cells, trigger degranulation, and produce an asthma attack within minutes.

Quantitative scale: IgE levels are normally low (~50 ng/mL) but can rise 100-1000× in atopic disease. Anti-IgE therapy (omalizumab) sequesters IgE, depriving mast cells of their sensitizing antibody and reducing attack frequency in moderate-to-severe asthma.

Antibody classes and their roles

Class	Serum %	Half-life	Effector function	Switching cytokines
IgM	~10%	~5 days	First response, pentameric, fixes complement strongly	Default — no switching needed
IgD	<1%	~3 days	BCR on naive B cells; soluble role unclear	Alternative splicing of μ/δ (not CSR)
IgG1	~65% of IgG	~21 days	Opsonization, complement, FcγR engagement, placenta	IFN-γ, IL-4 (variable)
IgG2	~20% of IgG	~21 days	Anti-polysaccharide; encapsulated bacteria	IFN-γ, TGF-β
IgG3	~7% of IgG	~7 days	Strongest complement fixation	IFN-γ
IgG4	~3% of IgG	~21 days	Chronic allergen exposure; immunotherapy marker	IL-4 + IL-10
IgA1	~13%	~6 days	Mucosal — gut, lung, saliva; secreted as dimer	TGF-β + IL-21 + retinoic acid
IgA2	(rare in serum, common in mucus)	~6 days	Resistant to bacterial IgA proteases	TGF-β + APRIL
IgE	<0.01%	~2 days (serum), weeks on mast cells	Mast cell sensitization, anti-helminth, allergy	IL-4, IL-13

IgA is the highest-volume antibody by mass per day — roughly 3-5 grams secreted into the gut lumen daily. IgG dominates serum concentration. IgE is rarest by mass but tissue-fixed on mast cells with weeks-long half-life there.

Molecular variants and pathway details

• Sequential switching. A B cell may switch from IgM to IgG1, then later from IgG1 to IgE upon re-exposure with IL-4. The intervening Cγ1 is already gone from the chromosome, so the second switch goes from Sγ1 to Sε directly. This is one way long-lived memory B cells transition during the natural history of allergic disease.
• Direct vs sequential. Some IgE responses go directly Sμ → Sε without an IgG intermediate; others go Sμ → Sγ1 → Sε in a two-step process. Direct switching produces IgE with lower somatic hypermutation; sequential produces higher-affinity IgE.
• Locus suicide recombination. Rarely, AID acts within constant regions themselves rather than switch regions, deleting an entire constant gene cluster and silencing the B cell. This is one mechanism of B-cell terminal differentiation.
• T-independent switching. Switching can occur without classic T-cell help via BAFF and APRIL signaling at TACI receptors on B cells — supports IgG and IgA against polysaccharide antigens in the marginal zone, but produces narrow repertoire and poor memory.
• AID off-targets. AID also mutates non-Ig loci — BCL6, MYC, BCL2, CD79B, and dozens of others. These off-target mutations and the chromosomal translocations they enable underlie B-cell lymphomas: t(14;18) puts BCL2 next to Igh; t(8;14) puts MYC next to Igh — both are AID-mediated.
• Class switching in plasma cells. Terminally differentiated plasma cells generally don't switch further — they're committed to one class. Long-lived bone marrow plasma cells maintain serum antibody for decades after vaccination on this basis.

Disease relevance

• Hyper-IgM syndromes. X-linked CD40L deficiency, autosomal CD40 deficiency, AID deficiency, UNG deficiency. Patients have high IgM, very low IgG/IgA/IgE, recurrent encapsulated bacterial infections, opportunistic infections (Pneumocystis), and lymphoid hyperplasia. AID-deficient patients have normal CD40L-CD40 signaling but cannot recombine — diagnostic feature.
• Common variable immunodeficiency (CVID). Heterogeneous group with reduced IgG (and often IgA and IgM). Many cases have defective germinal center reactions or class switching, sometimes due to ICOS, TACI, BAFF-R, or CD19 mutations. Lifelong immunoglobulin replacement; bronchiectasis from recurrent respiratory infections.
• IgA deficiency. The most common primary immunodeficiency (~1 in 600). Often asymptomatic; some have recurrent sinopulmonary infections or autoimmune disease. Caution with blood transfusions — IgA-deficient patients can produce anti-IgA and have anaphylactic transfusion reactions.
• Allergy. Inappropriate IgE class switching against environmental antigens. Mechanism is generally Th2-skewed cytokine context (IL-4, IL-13). Therapies: anti-IgE omalizumab, anti-IL-4Rα dupilumab, allergen immunotherapy that shifts switching toward IgG4.
• IgG4-related disease. Chronic fibroinflammatory disorder with elevated IgG4 and tissue infiltration by IgG4-plasma cells — affects pancreas (autoimmune pancreatitis), salivary glands (Mikulicz), retroperitoneum, biliary tract. Pathogenic role of IgG4 unclear; responds to steroids and rituximab.
• B-cell lymphomas. AID-mediated translocations cause Burkitt (t(8;14) MYC), follicular (t(14;18) BCL2), and others. Diffuse large B-cell lymphoma frequently arises in germinal centers; some carry classic translocations.
• Selective IgM deficiency. Rare; presents with infections and autoimmunity. Mechanism not always clear.

Common pitfalls and misconceptions

• "Class switching changes specificity." No. The V(D)J variable region is untouched. The same paratope binds the same epitope — just attached to a different Fc.
• "IgM means recent infection." Useful heuristic but often wrong — IgM can persist for months, IgM can be reactivated, and some pathogens (Lyme, syphilis) produce persistent IgM. Don't rely on IgM positivity alone for "acute" diagnosis.
• "All antibodies switch through germinal centers." Some switching occurs in extrafollicular foci — short-lived plasma cells produce IgG and IgA without entering germinal centers. These responses lack high-affinity maturation but appear earlier in the response.
• "IgG is one molecule." Four IgG subclasses (IgG1-4) have distinct effector functions: IgG1 and IgG3 fix complement and engage FcγR strongly; IgG2 targets polysaccharides; IgG4 is non-inflammatory and is favored after chronic allergen exposure or treatment-induced tolerance.
• "Class switching requires antigen specificity to be intact." Mostly. But cross-class switching can occur in IgG4-related disease and chronic infections in ways that change apparent serological reactivity.
• "AID only mutates immunoglobulin genes." AID has dozens of off-target sites that drive lymphomagenesis. The same enzyme that fuels antibody diversity is a tumor risk.

Therapeutic applications

• Conjugate vaccines. Linking T-independent polysaccharide antigens (pneumococcal capsule, meningococcal, Hib) to a protein carrier recruits T-cell help, enables class switching, and produces robust IgG and memory. Pure polysaccharide vaccines work poorly in children under 2 because their germinal center reactions and Tfh cooperation are immature.
• Allergen immunotherapy. Years of subcutaneous or sublingual allergen exposure shifts switching from IgE toward IgG4 — the blocking antibody that competes for allergen binding without triggering mast cells. Symptom reduction correlates with rising IgG4/IgE ratio.
• Omalizumab. Anti-IgE monoclonal that binds free IgE, prevents binding to FcεRI on mast cells, and reduces FcεRI expression. Approved for moderate-severe persistent asthma, chronic urticaria, food allergy.
• Dupilumab. Anti-IL-4Rα blocks IL-4 and IL-13 signaling, suppressing Th2 polarization and IgE class switching. Approved for atopic dermatitis, asthma, eosinophilic esophagitis, nasal polyposis.
• Intravenous/subcutaneous immunoglobulin (IVIG/SCIG). Pooled donor IgG replaces missing antibody in hyper-IgM, CVID, X-linked agammaglobulinemia, IgA deficiency with IgG subclass defects. Also used at higher doses as immunomodulator in autoimmune diseases.
• Rituximab and B-cell depletion. Anti-CD20 depletes mature B cells, including germinal center B cells before they switch — used in lymphoma, rheumatoid arthritis, multiple sclerosis, ANCA vasculitis.